Anavex Life Sciences Corp (AVXL)

[nidan7500]

hnnbadger1..Thanks for this ref. article. Some objective evidence of efficacy. finally "Our cup is (at least) half full". IMO.

[quote“These data are very exciting, particularly in a study that can demonstrate objective slowing of markers of neurodegeneration,” Michael Weiner, MD, professor of radiology and biomedical imaging, medicine, psychiatry, and neurology at the University of California, San Francisco (UCSF) and principal investigator of the Alzheimer's Disease Neuroimaging Initiative (ADNI) said in a statement.1

One of the most common treatment-emergent adverse events in the respective safety population was dizziness, which was transient and mostly mild to moderate in severity. This adverse event was reported in 120 participants (35.8%) during titration and in 76 participants (25.2%) during maintenance with blarcamesine. In comparison, this adverse effect occurred in 10 participants (6.0%) during titration and 9 (5.6%) during maintenance with placebo.

“Alzheimer disease is such a devastating disease that affects tens of millions worldwide, and Anavex’s clinical development is a testament to our determination to follow the science,” Christopher U Missling, PhD, president and chief executive officer of Anavex said in a statement.1 “We like to thank all the people involved in the study for their invaluable contributions and we look forward to advancing blarcamesine as a potential new convenient orally available treatment option for Alzheimer disease.”

REFERENCES
1. Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows NeurodegenerationSignificant Reduction of Amyloid Beta Biomarkers of Alzheimer’s Pathology. News Release. Anavex Life Sciences. Published September 14, 2023. Accessed September 15, 2023. https://www.anavex.com/post/anavex-sphase2b-3trialofblarcamesine-anavex-2-73-inpatientswithalzheimer-sdisease][/quote]